A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (NCT06003426)

🧪 Interventions in This Study

• BMS-986278 (DRUG)
• BMS-986278 Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (390 Sites)

Showing the first 25 of 390 sites.

• Local Institution - 0189 — Birmingham, Alabama
• Local Institution - 0361 — Phoenix, Arizona
• Local Institution - 0396 — La Jolla, California
• Local Institution - 0193 — Los Angeles, California
• Local Institution - 0398 — Los Angeles, California
• Local Institution - 0389 — Orange, California
• Local Institution - 0405 — Sacramento, California
• Local Institution - 0185 — San Francisco, California
• Local Institution - 0186 — Stanford, California
• Local Institution - 0363 — Aurora, Colorado
• Local Institution - 0194 — Denver, Colorado
• Local Institution - 0175 — New Haven, Connecticut
• Local Institution - 0151 — Newark, Delaware
• Local Institution - 0367 — Washington D.C., District of Columbia
• Local Institution - 0101 — Brandon, Florida
• Local Institution - 0436 — Clearwater, Florida
• Local Institution - 0425 — DeBary, Florida
• Local Institution - 0079 — Gainesville, Florida
• Local Institution - 0352 — Hialeah, Florida
• Local Institution - 0370 — Kissimmee, Florida
• Local Institution - 0502 — Leesburg, Florida
• Local Institution - 0153 — Loxahatchee Groves, Florida
• Local Institution - 0187 — Ocala, Florida
• Local Institution - 0418 — Pensacola, Florida
• Local Institution - 0206 — St. Petersburg, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

• Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
• A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
• Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
• MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.